2 completed, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
Follow Blushing: new trials by email Literature Review of Blushing trials Research Report on Blushing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Completed | AB Science | 135 | 2008-12-01 | 2019-12-03 |
| Gabapentin for the Treatment of Hot Flashes in Menopausal Women gabapentin - Hot Flashes, Menopause | Phase 3 | Completed | North Toronto Primary Care Research Network | 200 | 2004-03-01 | 2011-05-23 |
Mastocytosis (2) · Mastocytosis, Systemic (2) · Piebaldism (2) · Pruritus (2) · Hot Flashes (1)
Behavior (3) · Communication (3) · Nonverbal Communication (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Albinism (2) · Amino Acid Metabolism, Inborn Errors (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Hypopigmentation (2) · Immune System Diseases (2) · Mast Cell Activation Disorders (2) · Metabolic Diseases (2) · Metabolism, Inborn Errors (2)
masitinib (2) · Gabapentin (1)
AB Science (2) · North Toronto Primary Care Research Network (1)
France (2) · Canada (1) · Germany (1) · Netherlands (1) · Poland (1) · Romania (1) · Russia (1) · Ukraine (1) · United Kingdom (1) · United States (1)
Cristina Bulai Livideanu, MD, MSc (1) · Debra Butt, MSc MD CCFP (1) · Olivier Lortholary, MD, PhD (1)
2016 (1)